CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

NCT05251714 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Breast Cancer

Interventions

DRUG: CFI-402257
DRUG: Fulvestrant

Sponsor

Treadwell Therapeutics, Inc